Prana Scientist to Participate in Webcast to Discuss Alzheimer’s Disease Therapeutics: Recent Setbacks and Emerging Technologies on Monday, October 1

Melbourne – September 28, 2012; Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that Chief Scientific Advisor, Rudy Tanzi, Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School will take part in a webcast hosted by George Zavoico, Ph.D., Managing Director and Senior Analyst, of MLV & Co. The topic of the webcast will be: “Alzheimer’s Disease Therapeutics: Recent Setbacks and Emerging Alternatives.” The webcast will take place on Monday, October 1, at 2:00 pm Eastern Daylight Time (NYC).

The session will consider what are the most promising new technologies for fighting Alzheimer’s Disease which, with all other types of dementia, currently affects more than 36 million people worldwide. Participants will hear about innovative technologies and the best way forward for combating Alzheimer’s and other age related diseases. Professor Tanzi will address the potential impact of the recent failures of Pfizer’s bapineuzumab and Eli Lilly’s solanezumab Phase 3 trials and discuss the possible scientific reasons why they did not succeed.

Investors are invited to participate. To obtain dial-in information please contact: Leslie Goedken at 646-556-9206, lgoedken@mlvco.com; or Scott Ammaturo at 646-556-9218, sammaturo@mlvco.com. A toll free number from Australia will be provided for callers when they RSVP by phone or by email to the MLV names provided.